Narrow Label Will Restrict J&J’s Akeega In Prostate Cancer Combination Battle
But Helps Maintain Prostate Cancer Franchise
J&J has only been able to gain approval in BRCA-positive patients in the EU, while AstraZeneca’s rival combination can treat all metastatic prostate cancer patients.
